top of page

STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors

7 minutes ago

1 min read

Co-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of its antisense oligonucleotide that aims to restore expression, and also concurrently an investigator led study in China.

https://vimeo.com/1246103409?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

See All

STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in p2 psoriasis studies compared to existing products and might be dosed as little as once or twice a year - a key update will read next month

STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months

STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial human data on its oral PTH1R agonist for hypoparathyroidism in Q1

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more